NUCRYST Pharmaceuticals appoints Katherine J. Turner, PhD to Vice President, Research and Development

    WAKEFIELD, MA, June 27 /CNW/ - NUCRYST Pharmaceuticals is pleased to
announce that Katherine J. Turner, PhD has been appointed Vice President,
Research and Development. In this expanded role, Dr. Turner will be
responsible for guiding the research and development of the company's medical
product pipeline and will report to Scott H. Gillis, President & CEO, NUCRYST
Pharmaceuticals Corp.
    Dr. Turner has served as NUCRYST's Vice President, Research since June
2006. She will succeed Paul J. Schechter, MD, PhD, who is retiring effective
June 30, 2007.
    Prior to joining NUCRYST, Dr. Turner held the position of Vice President,
Validation Biology at Biogen Idec Inc., where she directed research in
immunology, neurobiology, fibrosis and oncology. Prior to this, Dr. Turner
rose through positions of increasing responsibilities at Genetics Institute
and its successor, Wyeth, to Vice President, Immunology and Hemostasis. She
has published extensively in peer-reviewed journals, authored chapters in
textbooks and presented research findings at symposia and professional
    "We are pleased to have Dr. Turner assume responsibility for research and
development. She is an accomplished scientist and biotechnology executive and
has extensive experience in healthcare product development," said Mr. Gillis.
"Dr. Turner will continue to play a pivotal role as we pursue our pipeline of
medical products."
    Dr. Schechter joined NUCRYST in 2002 and in addition to being the chief
medical officer, led the company's research and development program, as well
as regulatory affairs. He will provide continued support on a limited basis as
a medical director.
    "I want to thank Dr. Schechter for his years of service, dedication and
important contributions to NUCRYST," said Mr. Gillis. "He was instrumental in
establishing our pharmaceutical research and development program and his vast
experience helped identify numerous therapeutic targets based on our patented
atomically disordered nanocrystalline silver technology."

    NUCRYST Pharmaceuticals (NASDAQ:   NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using its patented atomically disordered nanocrystalline silver technology.
Smith & Nephew plc sell a range of advanced wound care products under their
Acticoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST's
SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also
developing pharmaceutical products to address medical conditions that are
characterized by both infection and inflammation. The Company has developed
its proprietary nanocrystalline silver in a powder form for use as an active
pharmaceutical ingredient, referred to as NPI 32101.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

    This news release may contain forward-looking statements within the
meaning of securities legislation in the United States and Canada. These
statements are based on current expectations that are subject to risks and
uncertainties, and the Company can give no assurance that these expectations
are correct. Various factors could cause actual results to differ materially
from those projected in such statements, including but not limited to: the
initiation, timing, progress and results of our preclinical and clinical
trials, research and development programs; our ability to implement our
business model and strategic plans for our business, product candidates and
technology; our ability to maintain and establish corporate collaborations;
changes in general economic conditions; financial considerations; other risks
and uncertainties unidentified at this time; and management's response to
these factors. The Company disclaims any intention or obligation to revise
forward-looking statements whether as a result of new information, future
developments or otherwise. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.

    %SEDAR: 00023031E

For further information:

For further information: David Wills, Investor Relations, (416)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890